Please login to the form below
Questcor
This page shows the latest Questcor news and features for those working in and with pharma, biotech and healthcare.
US piles pressure on Mallinckrodt over alleged Acthar fraud
The NDA approval was awarded to Acthar’s earlier owner Questcor, which was acquired by Mallinckrodt for $5.6bn in 2014.
Latest news
-
Humana lawsuit targets Mallinckrodt's 'billion-dollar golden goose'
Questcor allegedly increased the price to $750 immediately after buying the asset but the big jump was still to come. ... The price continued to tick up over the following years, both before and after Mallinckrodt paid $5.6bn to acquire Questcor in 2014
-
Mallinckrodt pays $1.2bn for Sucampo Pharma
bought Cadence Pharma for $1.3bn, Questcor for $6.5bn, immunotherapy outfit Therakos for $1.3bn and nuclear imaging specialist IBA Molecular for £690m in the last three years.
-
Ireland's Mallinckrodt buys US regenerative medicine firm
Ikaria. In the previous year it shelled out $5.6bn for Questcor Pharma - getting hold of fast-growing autoimmune and inflammatory drug Acthar (repository corticotropin injection) - and another $1.3bn for
-
Ireland’s Mallinckrodt makes $1.3bn immunotherapy purchase
This includes the $5.6bn deal for Questcor Pharmaceuticals last year and its purchase of Cadence Pharmaceuticals for $1.3bn.
-
Mallinckrodt cuts $5.6bn deal to buy Questcor
Under the terms of the deal, Questcor's shareholders will receive $30 in cash and 0.897 Mallinckrodt shares for each share they own. ... Trudeau will be CEO of the combined company, while three other Questcor executive, including CEO Don Bailey, will
More from news
Approximately 2 fully matching, plus 9 partially matching documents found.
Latest Intelligence
-
Deal Watch table for April 2014
7, 100. Questcor/ Mallinckrodt. Acquisition. Acthar Gel (repository corticotropin) for “difficult-to-treat” autoimmune/ inflammatory conditions.
-
Pharma deals during April 2014
Of the remaining 18 top 21 deals this month, 12 involved wholesale takeovers with deals in Devices (Biomet/ Zimmer Holdings, AccessClosure/ Cardinal Health; New Wave Surgical/ Covidien), Generics/ Speciality Pharma (Questcor/ ... Whilst this is a 60-year
-
Deal Watch table for June 2013
165. Novartis / Questcor. Development rights. Rights to develop Synacthen (tetracosactide, melanocortin receptor agonist) and Synacthen Depot (approved in Europe for autoimmune &inflammatory conditions).
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Latest appointments
-
Questcor appoints SVP corporate strategic development
Michael Aldridge joins from Australian early development company Xenome. US biopharma Questcor Pharmaceuticals has named Michael Aldridge as its first senior VP, corporate strategic development. ... Development programmes that complement Acthar are also
More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Lead Market Access Writer, £5K joining bonus, UK
-
Highly competitive salary
- Principal Medical Writer/ Scientific Lead, Medcomms, £5K joining...
-
Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
-
Highly competitive salary
- Exciting Medical Writer Career Opportunity for Postdoc, Medcomms
-
Highly competitive salary
- World Health Organization releases latest set of COVID-19 guidelines
- Europe’s cancer community publishes new report on transforming patient care
- BeiGene’s Brukinsa receives FDA approval for chronic lymphocytic leukaemia
- AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced breast cancer
- Eli Lilly announces $450m investment in US manufacturing site
- EU outlines measures to mitigate antibiotic shortage across Europe
- Innovative Trials comments on extra funding to increase access to clinical trials for cancer patients
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- JCVI recommends autumn COVID-19 vaccine booster for those at highest risk
- MIT researchers develop AI model to detect future lung cancer risk
- Merging global and local pharmacovigilance operations into a successful integrated approach
- Diversifying Healthcare AI with Federated Learning
- FDA and CDC investigate potential safety concern for Pfizer/BioNTech’s COVID-19 vaccine
- World Health Organization releases latest set of COVID-19 guidelines
- AbbVie and Eli Lilly leave UK’s voluntary drug pricing agreement
- AbbVie trial backs chemo-free Imbruvica combo regimen
- AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced breast cancer
- EU to revise pharmaceuticals law amid antibiotic shortages
PMHub
Evoke Kyne
Evoke Kyne is an award-winning communications agency that harnesses insight, experience and creativity to advance health and wellbeing around the world. We were founded on the belief that...
Latest intelligence
- Virtual Steering Committee & Peer Influence Program
- In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program....
- Meeting healthcare’s rising challenges
- The journey to discover novel therapies through digital innovation and ensure scientific advances achieve their potential...
- Report gives insights to address gaps in HCP engagement
- How does Pharma-HCP engagement need to evolve in today's digital landscape?...
